A LTHOUGH TWIN AND family-based studies show that about 50% of alcohol dependence (AD) risk is heritable, replicable findings have identified few corresponding genetic variants. Using a known variant, we used electronic health record (EHR) data to develop and validate a phenotype for harmful alcohol exposure that could be used to identify unknown genetic variants in large samples. Linkage and candidate gene studies have consistently identified risk loci for the genes encoding the alcohol-metabolizing enzymes (Foroud et al., 2010) . Similar findings have emerged from genomewide association studies (GWAS) (Hart and Kranzler, 2015) . A major limitation to gene finding for AD is the relatively small sample size of many of the published studies. The largest GWAS of AD to date included a discovery and replication sample of 16,087 subjects (Gelernter et al., 2014) . That study confirmed previously identified risk loci mapped to the alcohol-metabolizing enzyme genes ADH1B in both European Americans (Arg48His or rs1229984, p = 1.17 9 10
À31
) and African Americans (AAs; Arg369Cys or rs2066702, p = 6.33 9 10
À17
) and ADH1C in AAs (Thr151Thr or rs2241894, p = 4.94 9 10 À10 ). The study also identified numerous novel significant risk loci, across the alcohol dehydrogenase (ADH) gene array region and elsewhere. Because these variants account for only a small percentage of the heritability of AD, large-scale studies to identify additional loci are warranted. The Million Veteran Program (MVP) of the Department of Veterans Affairs is in the process of obtaining phenotypic and genomic data on 1 million people. One goal of the MVP is to identify genetic variation contributing to AD risk.
A challenge in a large-scale study is the ability to identify a valid AD phenotype efficiently. Because AD is a complex trait and comparatively small samples of alcoholdependent subjects have been studied to date using GWAS, it is not surprising that few specific variants have been implicated consistently (Hart and Kranzler, 2015) . EHR data are a potentially important source of phenotypic information. As MVP investigators, we sought to develop an EHR-based approach that went beyond administrative diagnostic codes for alcohol use disorder, which can be insensitive (McGinnis et al., 2010 (McGinnis et al., , 2013 . Alcohol screening questionnaires, which are increasingly used in routine clinical care, could provide an alternative. One such instrument is the Alcohol Use Disorders Identification Test (AUDIT; Saunders et al., 1993) , a 10-question, self-report screening test for harmful alcohol use. The AUDIT-C, which includes only the first 3 (quantity and frequency) questions of the AUDIT, is a practical, valid, primary care screening test for heavy drinking and/ or active alcohol abuse or dependence. Developed using questionnaire and telephone interview data from 243 patients at 3 Veterans Affairs (VA) general medical clinics (Bush et al., 1998) , it has become the most popular short version of the AUDIT. The 3-item AUDIT-C demonstrated greater accuracy for heavy drinking than the full AUDIT and performed similarly in detecting heavy drinking and/or active alcohol abuse or dependence (Bush et al., 1998) . Since 2007, the AUDIT-C has been a required annual screening test in primary care in the Veterans Affairs Health System (VAHS), where it has high sensitivity and specificity for alcohol use disorders (Barnes et al., 2010; McGinnis et al., 2013) . Although the AUDIT-C is widely used, inaccurate reporting could limit its utility in identifying AD genetic variants. In contrast, an alcohol biomarker should provide an unbiased estimate, but is not readily available in large samples.
We first compared 3 AUDIT-C metrics (closest, highest, trajectory) to each other. Second, we compared the 3 AUDIT-C metrics to see which demonstrated the strongest association with a direct alcohol biomarker, phosphatidylethanol (PEth). Last, we compared the associations of the 3 AUDIT-C metrics with rs2066702, the Arg369Cys missense polymorphism of the ADH1B gene, which encodes an ADH isozyme that is common in African Americans (AAs).
MATERIALS AND METHODS

Subjects
The Veterans Aging Cohort Study Biomarker Cohort (VACS-BC) has been described in detail previously (Armah et al., 2012; Freiberg et al., 2016; Justice et al., 2012) . Briefly, it is a smaller sample, nested within a large observational cohort based on data from the national VA EHR that includes all HIV-infected patients in VA care (over 50,000 HIV+ subjects) and uninfected patients (over 100,000) matched on region, age, race/ethnicity, and sex. The biomarker cohort includes 1,525 HIV+ and 843 uninfected individuals who provided a blood sample in 2005 to 2007 (Armah et al., 2012; Justice et al., 2012; So-Armah et al., 2012) . We used AUDIT-C data collected during routine clinical care from 2007 (when first available from EHR extracts) to 2016, note that AUDIT-C data are from a later time frame than PEth. In the analyses comparing AUDIT-C metrics to each other and to PEth, we included participants for whom AUDIT-C data were available in the EHR and who had PEth values (n = 1,851). The analysis comparing AUDIT-C to presence/absence of the ADH1B 369Cys allele was limited to 1,503 AAs with genotype and AUDIT-C data, as this particular variant is rare in most other racial/ethnic groups. In this sample, the 369Cys allele was present in 36% of AAs, 0.3% of whites, and 6% of all others. A total of 1,342 participants were in both analytic samples.
Measures AUDIT-C. The 3 AUDIT-C questions are as follows: (i) How often do you have a drink containing alcohol? (choices: never; monthly or less; 2 to 4 times a month; 2 to 3 times a week; or 4 or more times a week). (ii) How many standard drinks containing alcohol do you have on a typical day? (choices: 1 or 2; 3 or 4; 5 or 6; 7 to 9; or 10 or more). (iii) How often do you have 6 or more drinks on 1 occasion? (choices: never; less than monthly; monthly; weekly; daily or almost daily). Responses to each question are assigned 0 to 4 points, yielding a total score of 0 to 12. AUDIT-C screening thresholds that maximize sensitivity and specificity for detecting unhealthy alcohol use are ≥4 in men and ≥3 in women, with the likelihood in both sexes of alcohol-related harm increasing as AUDIT-C scores increase (Bradley et al., 2007; Bush et al., 1998) .
Phosphatidylethanol. PEth assays were run on dried blood spots created from frozen peripheral blood mononuclear cells stored at À80°C. PEth comprises a group of phospholipids formed from phosphatidylcholine by the action of phospholipase D following the ingestion of alcohol (Helander and Zheng, 2009) . PEth can be assayed in whole blood or from dried blood spots using liquid chromatography and mass spectrometry. According to the test laboratory, the United States Drug Testing Laboratories, Inc. (USDTL), the limit of detection is 2 ng/ml and the lower limit of quantitation is 8 ng/ml. The concentration of PEth is linearly related to the volume of alcohol consumed (Aradottir et al., 2006) . A cutoff of 20 ng/ml is used for forensic work and levels >100 ng/ml indicate heavy drinking (J. Jones, USDTL, personal communication). PEth concentrations >500 ng/ml are typically seen in individuals with prolonged heavy drinking (Wurst et al., 2015) . Because PEth has a half-life of~4 days, it can be assayed in the blood of heavy drinkers for up to 3 weeks after alcohol is consumed (Wurst et al., 2015) . The sensitivity of PEth has been reported to be 99% (Aradottir et al., 2006) , with several studies showing the assay to have perfect specificity, including in the presence of liver disease and hypertension. A major advantage of PEth is that, unlike many other candidate alcohol biomarkers, it does not appear to be influenced by age, gender, other ingested substances, or nonalcohol-associated diseases (Viel et al., 2012) .
Arg369Cys. Variation in ADH1B is the most frequently identified molecular genetic risk factor for AD. The variant 369Cys allele is associated with reduced risk of AD (Gelernter et al., 2014) . More than half of the DNA samples in the present study (N = 1,291) were genotyped on the Illumina HumanOmniExpress Beadchip (Illumina, Inc., San Diego, CA) containing 980,000 single nucleotide polymorphisms (SNPs) including rs2066702. The rest (N = 955) were genotyped on the Illlumina HumanCoreExome BeadChip containing approximately 550,000 SNPs, which did not include rs2066702. In these samples, the SNP was imputed based on 1000 Genomes phase 3 data (http://www.1000genomes.org/about) using IMPUTE 2 (https://mathgen.stats.ox.ac.uk/impute/impute_v2. html).
Analyses
Using all available EHR AUDIT-C measurements, we created 3 AUDIT-C metrics: (i) a cross-sectional score using the value closest to the date of blood sampling and 2 longitudinal measures; (ii) the highest AUDIT-C value over the period 2007 to 2016; and (iii) the trajectory of AUDIT-C scores. We differentiated the closest and highest AUDIT-C scores into categories: 0, 1, 2 to 3, and 4+; the highest category is based on prior work showing AUDIT-C 4+ as maximizing the sensitivity and specificity for identifying unhealthy alcohol use in men (Bradley et al., 2007; Bush et al., 1998) . As previously reported (Marshall et al., 2015) , joint trajectory modeling sorts each participant's AUDIT-C values into "clusters" and estimates distinct trajectories. We used age as the time scale to account for decreased alcohol use with age. The procedure calculates each individual's probability of belonging to each trajectory and assigns the individual to the trajectory with the highest probability of membership. We used a zero-inflated Poisson model (Jones et al., 2001 ) and evaluated 3-, 4-and 5-group models. For maximum precision, trajectories were developed in the full VACS sample.
First, we compared the 3 AUDIT-C metrics (closest, highest, and trajectory) using the following pairwise comparisons: closest versus highest; closest versus trajectory; and highest versus trajectory. We also generated Spearman correlation coefficients between the 3 AUDIT-C metrics. Next, median PEth values were summarized and categorized by cutoff values (≥8, ≥20, ≥100 ng/ml). The associations of the 3 AUDIT-C metrics with PEth were tested using nonparametric tests for trend for continuous PEth values and chisquare tests for trend for dichotomous PEth variables. Among AAs, the associations of AUDIT-C metrics with rs2066702 were tested using chi-square tests for trend.
RESULTS
Both the AUDIT-C and PEth sample and the AUDIT-C and ADH1B variant subset were mostly male (95%), with a median age of 52 years at blood sampling, and about 65% were HIV+ (Table 1) . Nearly three-fourths of the overall sample were AA. Agreement between self-report and genetic markers for race (kappa = 0.85) and sex (kappa = 0.98) was excellent.
AUDIT-C trajectory fit, as measured by the Bayesian information criterion, improved substantially when increasing from 3 to 4 groups, but only slightly between 4 and 5 groups. Lower-level group membership was stable, with differences in assignment occurring only at the higher AUDIT-C levels. In the analytic sample, the highest level of the 4-group model contained 98 people. We chose the 4-group model to avoid unstable estimates that could result from using a 5-group model with even fewer subjects in the highest level. The AUDIT-C trajectory groups were designated as infrequent, lower risk, potentially hazardous, and consistently hazardous.
There were differences in how participants were classified using the 3 AUDIT-C metrics. A comparison of groups based on the AUDIT-C closest to the PEth date with groups based on the highest AUDIT-C showed that 43% of subjects were classified in a higher group using the longitudinal metric (Table 2a) . Comparing closest AUDIT-C with AUDIT-C trajectory, 38% of subjects were classified differently using the longitudinal metric (Table 2b ): 18% to a lower group and 20% to a higher group. Comparing highest AUDIT-C groups with AUDIT-C trajectories (Table 2c ), 54% were classified in a lower category with the trajectory metric. Correlation coefficients for the 3 AUDIT-C metrics were 0.55 for closest and highest, 0.56 for closest and trajectory, and 0.86 for the 2 longitudinal metrics: highest and trajectory.
AUDIT-C metrics were associated with PEth values (Fig. 1) . Median time between PEth and closest AUDIT-C was 2.3 years (interquartile range [IQR] = 1.7 to 2.8). All 3 AUDIT-C metrics (closest, highest, and trajectory) were associated with PEth values (median and PEth thresholds 8+, 20+ and 100+). This was true both when all race/ethnicities were included and when just AAs were included, all p < 0.001 (Fig. 1A,B) . AUDIT-C trajectory demonstrated the steepest gradient, followed by closest AUDIT-C, with highest AUDIT-C showing the lowest gradient. The proportion of AAs with the 369Cys allele decreased significantly as the highest and trajectory AUDIT-C metrics increased (Fig. 2) . The closest AUDIT-C was not statistically significantly associated with rs2066702.
DISCUSSION
We found that EHR data can be used to phenotype a complex condition such as harmful alcohol use. The validity of the phenotype was enhanced when longitudinal data were integrated using trajectories or highest value rather than with a single cross-sectional measure. All 3 AUDIT-C metrics were associated with PEth concentrations, a highly sensitive and specific measure of heavy drinking (Wurst et al., 2015) . Closest AUDIT-C scores were not significantly associated with the most frequently identified molecular genetic risk factor for AD, a missense polymorphism in ADH1B, which encodes an alcohol metabolic enzyme. Highest AUDIT-C score was statistically significantly associated with the ADH1B polymorphism, rs2066702. However, AUDIT-C trajectory showed a steeper gradient and a robust and significant association with the variant. This is likely because the trajectory score provides greater information on the pattern of harmful drinking over time than either of the other 2 AUDIT-C metrics, and is thereby more reflective of typical alcohol exposure than either a single point in time or peak exposure.
A limitation of our study is that there is a gap in time between when AUDIT-C was measured (2005 to 2007) and when the PEth and ADH1B samples were collected (2007 to 2016) . Similarly, the long-term stability of PEth in frozen blood samples is unknown. Faller and colleagues (2013) found no assay loss in samples stored for 30 days at À80°C. We would expect that any bias introduced by the gap between AUDIT-C and sample collection, or possible sample degradation while in storage, would be toward the null. However, we found strong associations between PEth and all 3 AUDIT-C metrics, similar to those reported by Piano and colleagues (2015) from samples not subject to lengthy storage. Thus, we find the consistency of biomarker results and self-report reassuring. ADH1B genotype does not change over time, so the difference in time between EHR AUDIT-C and ADH1B genotype is not relevant.
Our findings extend the current literature, in which the most common approach to defining a phenotype for harmful alcohol consumption has been the diagnosis of alcohol use disorder based on the DSM. While this phenotype has clinical utility, it is time-consuming and costly to obtain, substantially limiting large-scale genetic discovery. Although it may also be tempting to use the International Classification of Diseases administrative codes as a phenotype for large-scale discovery, these tend to be highly insensitive measures (McGinnis et al., 2010 (McGinnis et al., , 2013 . By first validating a set of AUDIT-C measures against a direct alcohol biomarker (PEth) and then comparing their association with an established molecular genetic factor that is protective against harmful alcohol use, we were able to demonstrate the superiority of AUDIT-C trajectories over both the highest and closest AUDIT-C metrics.
These findings indicate that useful phenotypes for complex behaviors like alcohol use can be obtained using longitudinal EHR data, but the quality of the phenotype may depend upon the length of the observation period and the statistical approach used to calculate the metric. Our sample had an average of 7 AUDIT-C measurements collected over an average of more than 6 years. While our sample size did not allow us to explore the extent to which the more robust associations with PEth and ADH1B seen with the trajectories depended upon the number of observations or the time interval covered, we were able to demonstrate the superiority of trajectories over both single measure metrics. Of note, while the majority of healthcare systems have adopted EHRs and many use the AUDIT-C to screen for harmful drinking, the VAHS is one of the few healthcare systems that currently have longitudinal data spanning more than 6 years. Our focus on AAs both strengthened and limited the study. Few prior studies have focused on phenotyping harmful alcohol use for genetic discovery among AAs. However, our sample was large enough to examine the validity of the AUDIT-C only in AAs. Because another ADH1B missense polymorphism, Arg48His, has been shown to be protective from AD in Asians (Li et al., 2011) and European Americans (Bierut et al., 2012; Gelernter et al., 2014) , the same approach could be used to evaluate the AUDIT-C in these populations. Despite being limited to 1 population, the findings reported here indicate that longitudinal AUDIT-C data provide a valid metric of harmful alcohol use that may be a useful phenotype for genetic discovery. Because the AUDIT-C is a widely used screening measure, when administered as a repeated metric of harmful drinking, it may provide an important source of phenotypic information for large-scale genetic studies.
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